Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan

References

• SimonneauGRobbinsIMBeghettiMUpdated clinical classification of pulmonary hypertensionJ Am Coll Cardiol200954Suppl 1S43S5419555858
   PubMed Web of Science ®Google Scholar
• DalientoLSomervilleJPresbiteroPEisenmenger syndrome. Factors relating to deterioration and deathEur Heart J19981912184518559886728
   PubMed Web of Science ®Google Scholar
• FarberHWLoscalzoJPulmonary arterial hypertensionN Engl J Med2004351161655166515483284
   PubMed Web of Science ®Google Scholar
• EngelfrietPMDuffelsMGJMöllerTPulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart diseaseHeart200793668268717164490
   PubMed Web of Science ®Google Scholar
• EngelfrietPMeijboomFBoersmaETijssenJMulderBRepaired and open atrial septal defects type II in adulthood: an epidemiological study of a large European cohortInt J Cardiol2008126337938517586067
   PubMed Web of Science ®Google Scholar
• DuffelsMGJvan der PlasMNSurieSBosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolismNeth Heart J200917933433819949475
   PubMed Web of Science ®Google Scholar
• TrojnarskaOPlaskotaKTherapeutic methods used in patients with Eisenmenger syndromeCardiol J200916650050619950085
   PubMed Web of Science ®Google Scholar
• DuffelsMGJVisJCvan LoonRLEDown patients with Eisenmenger syndrome: is bosentan treatment an option?Int J Cardiol2009134337838318579234
   PubMed Web of Science ®Google Scholar
• DimopoulosKInuzukaRGolettoSImproved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertensionCirculation20101211202520026774
   PubMed Web of Science ®Google Scholar
• PresbiteroPSomervilleJStoneSPregnancy in cyanotic congenital heart disease. Outcome of mother and fetusCirculation1994896267326768205680
   PubMed Web of Science ®Google Scholar
• BergerRMFBeghettiMGalièNAtrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger syndrome: A subgroup analysisInt J Cardiol2009520 [Epub ahead of print].
   Web of Science ®Google Scholar
• HopkinsWRubinLJTreatment of pulmonary hypertension2009 Available from: http://www.uptodate.com/home/content/topic.do?topicKey=ven_pulm/11621. Accessed on Aug 2, 2010.
   Google Scholar
• FarberHWLoscalzoJPulmonary arterial hypertensionN Engl J Med2004351161655166515483284
   PubMed Web of Science ®Google Scholar
• KenyonKWNappiJMBosentan for the treatment of pulmonary arterial hypertensionAnn Pharmacother2003377–81055106212841819
   PubMed Web of Science ®Google Scholar
• ValerioJGCBosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patientVasc Health Risk Manage20095607619
   PubMedGoogle Scholar
• MotteSMcEnteeKNaeijeREndothelin receptor antagonistsPharmacol Ther2006110338641416219361
   PubMed Web of Science ®Google Scholar
• YoshibayashiMNishiokaKNakaoKPlasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulationCirculation1991846228022851959183
   PubMed Web of Science ®Google Scholar
• PietraGGCapronFStewartSPathologic assessment of vasculopathies in pulmonary hypertensionJ Am Coll Cardiol20044312 Suppl SS25S32
   PubMed Web of Science ®Google Scholar
• OpitzCFEwertRKirchWPittrowDInhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?Eur Heart J200829161936194818562303
   PubMed Web of Science ®Google Scholar
• DingemanseJvan GiersbergenPLMClinical pharmacology of bosentan, a dual endothelin receptor antagonistClin Pharmacokinet200443151089111515568889
   PubMed Web of Science ®Google Scholar
• DuffelsMGJEngelfrietPMBergerRMFPulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registryInt J Cardiol2007120219820417182132
   PubMed Web of Science ®Google Scholar
• GuyattGHSullivanMJThompsonPJThe 6-minute walk: a new measure of exercise capacity in patients with chronic heart failureCan Med Assoc J198513289199233978515
   PubMed Web of Science ®Google Scholar
• BarstRJMcGoonMTorbickiADiagnosis and differential assessment of pulmonary arterial hypertensionJ Am Coll Cardiol20044312 Suppl SS40S47
   Web of Science ®Google Scholar
• MiyamotoSNagayaNSatohTClinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testingAm J Respir Crit Care Med20001612 Pt 148749210673190
   PubMed Web of Science ®Google Scholar
• VisJCThoonsenHDuffelsMGSix-minute walk test in patients with Down syndrome: validity and reproducibilityArch Phys Med Rehabil20099081423142719651279
   PubMed Web of Science ®Google Scholar
• DuffelsMGJVisJCvan LoonRLEEffect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndromeAm J Cardiol200910391309131519406277
   PubMed Web of Science ®Google Scholar
• BarstRJMcGoonMTorbickiADiagnosis and differential assessment of pulmonary arterial hypertensionJ Am Coll Cardiol20044312 Suppl SS40S47
   Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonOEffects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet200135892881119112311597664
   PubMed Web of Science ®Google Scholar
• GalièNBeghMGatMBosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigator. Bosentan therapy in patients with Eisenmenger Syndrome: a multicenter, double-blind, randomized, placebo-controlled studyCirculation2006114485416801459
   PubMed Web of Science ®Google Scholar
• GatzoulisMABeghettiMGalièNLonger-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension studyInt J Cardiol20081271273217658633
   PubMed Web of Science ®Google Scholar
• GalièNRubinLHoeperMTreatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY Study)Lancet20083712093210018572079
   PubMed Web of Science ®Google Scholar
• D’AltoMVizzaCDRomeoEea Long-term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and hemodynamic effectHeart200793562162517135220
   PubMed Web of Science ®Google Scholar
• DillerGDimopoulosKKayaMGLong-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart diseaseHeart200793897497617639112
   PubMed Web of Science ®Google Scholar
• ApostolopoulouSCManginasACokkinosDVRammosSLong-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year studyHeart200793335035416980516
   PubMed Web of Science ®Google Scholar
• NorthridgeDBGrantSFordINovel exercise protocol suitable for use on a treadmill or a bicycle ergometerBr Heart J19906453133162245110
   PubMedGoogle Scholar
• GalièNManesANegroLA meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEur Heart J200930439440319155250
   PubMed Web of Science ®Google Scholar
• van LoonRLEHoendermisESDuffelsMGJLong-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?Am Heart J2007154477678217893008
   PubMed Web of Science ®Google Scholar
• JingZStrangeGZhuXEfficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertensionJ Heart Lung Transplant201029215015620113907
   PubMedGoogle Scholar
• DuffelsMGJHardziyenkaMSurieSDuration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertensionEur J Echocardiogr200910343343819042941
   PubMed Web of Science ®Google Scholar
• HumbertMSegalESKielyDGResults of European post-marketing surveillance of bosentan in pulmonary hypertensionEur Respir J200730233834417504794
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonOstudy 351 Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet200135892881119112311597664
   PubMed Web of Science ®Google Scholar
• HumbertMBarstRJRobbinsIMBREATHE-2 combination of bosentan with epoprostenol in pulmonary arterial hypertensionEur Respir J200424335335915358690
   PubMed Web of Science ®Google Scholar
• KeoghAMMcNeilKDWlodarczykJGabbayEWilliamsTJQuality of life in pulmonary arterial hypertension: improvement and maintenance with bosentanJ Heart Lung Transplant200726218118717258153
   PubMed Web of Science ®Google Scholar
• ApostolopoulouSCManginasACokkinosDVRammosSEffect of the oral endothelin antagonist bosentan on the clinical, exercise, and hemodynamic status of patients with pulmonary arterial hypertension related to congenital heart diseaseHeart200591111447145215761050
   PubMed Web of Science ®Google Scholar
• BeghettiMGalièNEisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertensionJ Am Coll Cardiol200953973374019245962
   PubMed Web of Science ®Google Scholar
• HoeperMMMarkevychISpiekerkoetterEWelteTNiedermeyerJGoal-oriented treatment and combination therapy for pulmonary arterial hypertensionEur Respir J200526585886316264047
   PubMed Web of Science ®Google Scholar
• BurgessGHoogkamerHCollingsLDingemanseJMutual pharmacokinetic interactions between steady-state bosentan and sildenafilEur J Clin Pharmacol2008641435018040672
   PubMed Web of Science ®Google Scholar
• GalièNTorbickiABarstRGuidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of CardiologyEur Heart J200425242243227815589643
   PubMed Web of Science ®Google Scholar
• McLaughlinVVArcherSLBadeschDBACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension AssociationJ Am Coll Cardiol200953171573161919389575
   PubMed Web of Science ®Google Scholar